Aflibercept biosimilar (Shilpa Biologicals)

阿柏西普生物类似药 (Shilpa Biologicals)

Report date: 2024/08/21 14:09:31

Base Information

Drug NameAflibercept biosimilar (Shilpa Biologicals)
Drug Alias NameSBDM-03
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein
Mechanisms of ActionPlacental Growth Factor inhibitorsVascular endothelial growth factor A inhibitors
TargetsPlacental Growth FactorVascular endothelial growth factor A
Therapy Area/IndicationsWet age-related macular degeneration
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryIndia
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesShilpa Biologicals Pvt Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShilpa Biologicals Pvt Ltd
Inactive CompaniesN/A
Active IndicationsWet age-related macular degeneration
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A